Matches in SemOpenAlex for { <https://semopenalex.org/work/W2516590051> ?p ?o ?g. }
Showing items 1 to 92 of
92
with 100 items per page.
- W2516590051 endingPage "8097" @default.
- W2516590051 startingPage "8097" @default.
- W2516590051 abstract "8097 Background: We evaluated the efficacy and safety of amrubicin, a third generation synthetic anthracycline, in combination with cyclophosphamide, vincristine and prednisolone (ACOP) in patients with previously untreated aggressive non-Hodgkin's lymphoma (NHL). Methods: Previously untreated patients with intermediate or high grade NHL were treated with 8 cycles of amrubicin, 100 mg/m2, cyclophosphamide, 750 mg/m2, and vincristine, 1.4 mg/m2 (maximum 2.0 mg), on day 1, and prednisolone, 60 mg/m2/day day 1-5 every 21 days. Patients were evaluated for response and left ventricular ejection fraction (LVEF) every 2 cycles, and electrocardiogram at every cycle. The primary endpoint was response rate; secondary endpoints were survival, cardiac safety, and general safety. Results: Fifty-six patients were eligible and received a median of 8 treatment cycles. The median follow- up period was 57.1 months. Most patients had diffuse large B-cell lymphoma (76.8%). The response rate was 92.9%; the complete response (CR) and CRu rate was 69.6%. The 2- and 5-years survival rates were 76.2% and 58.7%, respectively. Reversible myelosuppression was the most common adverse event. Grade 3/4 neutropenia, anemia, thrombocytopenia and febrile neutropenia were reported in 82.5%, 19.3%, 8.8% and 7% of patients, respectively. There were no treatment-related deaths or patients experiencing cardiomyopathy. LVEF did not change during the course of treatment. Conclusions: The response rate and survival in non-Hodgkin's lymphoma patients treated with ACOP were comparable to those achieved with CHOP in other studies, but ACOP had virtually no reduction of LVEF up to a cumulative amrubicin dose of 800 mg/m2. This suggests that amrubicin has little chronic cardiotoxicity. ACOP should be evaluated in combination with rituximab (R) and then compared to R-CHOP. No significant financial relationships to disclose." @default.
- W2516590051 created "2016-09-16" @default.
- W2516590051 creator A5018155332 @default.
- W2516590051 creator A5038809462 @default.
- W2516590051 creator A5043626530 @default.
- W2516590051 creator A5045331398 @default.
- W2516590051 creator A5046638834 @default.
- W2516590051 creator A5053647194 @default.
- W2516590051 creator A5062990172 @default.
- W2516590051 creator A5075837197 @default.
- W2516590051 creator A5088240103 @default.
- W2516590051 date "2010-05-20" @default.
- W2516590051 modified "2023-09-23" @default.
- W2516590051 title "Late phase II study of amrubicin in previously untreated patients with non-Hodgkin's lymphoma (NHL)." @default.
- W2516590051 doi "https://doi.org/10.1200/jco.2010.28.15_suppl.8097" @default.
- W2516590051 hasPublicationYear "2010" @default.
- W2516590051 type Work @default.
- W2516590051 sameAs 2516590051 @default.
- W2516590051 citedByCount "0" @default.
- W2516590051 crossrefType "journal-article" @default.
- W2516590051 hasAuthorship W2516590051A5018155332 @default.
- W2516590051 hasAuthorship W2516590051A5038809462 @default.
- W2516590051 hasAuthorship W2516590051A5043626530 @default.
- W2516590051 hasAuthorship W2516590051A5045331398 @default.
- W2516590051 hasAuthorship W2516590051A5046638834 @default.
- W2516590051 hasAuthorship W2516590051A5053647194 @default.
- W2516590051 hasAuthorship W2516590051A5062990172 @default.
- W2516590051 hasAuthorship W2516590051A5075837197 @default.
- W2516590051 hasAuthorship W2516590051A5088240103 @default.
- W2516590051 hasConcept C121608353 @default.
- W2516590051 hasConcept C126322002 @default.
- W2516590051 hasConcept C141071460 @default.
- W2516590051 hasConcept C197934379 @default.
- W2516590051 hasConcept C203092338 @default.
- W2516590051 hasConcept C2776694085 @default.
- W2516590051 hasConcept C2776715498 @default.
- W2516590051 hasConcept C2776755627 @default.
- W2516590051 hasConcept C2776802502 @default.
- W2516590051 hasConcept C2777063308 @default.
- W2516590051 hasConcept C2778198053 @default.
- W2516590051 hasConcept C2778476033 @default.
- W2516590051 hasConcept C2778476748 @default.
- W2516590051 hasConcept C2778850193 @default.
- W2516590051 hasConcept C2779338263 @default.
- W2516590051 hasConcept C2779429289 @default.
- W2516590051 hasConcept C530470458 @default.
- W2516590051 hasConcept C535046627 @default.
- W2516590051 hasConcept C71924100 @default.
- W2516590051 hasConcept C78085059 @default.
- W2516590051 hasConcept C90924648 @default.
- W2516590051 hasConceptScore W2516590051C121608353 @default.
- W2516590051 hasConceptScore W2516590051C126322002 @default.
- W2516590051 hasConceptScore W2516590051C141071460 @default.
- W2516590051 hasConceptScore W2516590051C197934379 @default.
- W2516590051 hasConceptScore W2516590051C203092338 @default.
- W2516590051 hasConceptScore W2516590051C2776694085 @default.
- W2516590051 hasConceptScore W2516590051C2776715498 @default.
- W2516590051 hasConceptScore W2516590051C2776755627 @default.
- W2516590051 hasConceptScore W2516590051C2776802502 @default.
- W2516590051 hasConceptScore W2516590051C2777063308 @default.
- W2516590051 hasConceptScore W2516590051C2778198053 @default.
- W2516590051 hasConceptScore W2516590051C2778476033 @default.
- W2516590051 hasConceptScore W2516590051C2778476748 @default.
- W2516590051 hasConceptScore W2516590051C2778850193 @default.
- W2516590051 hasConceptScore W2516590051C2779338263 @default.
- W2516590051 hasConceptScore W2516590051C2779429289 @default.
- W2516590051 hasConceptScore W2516590051C530470458 @default.
- W2516590051 hasConceptScore W2516590051C535046627 @default.
- W2516590051 hasConceptScore W2516590051C71924100 @default.
- W2516590051 hasConceptScore W2516590051C78085059 @default.
- W2516590051 hasConceptScore W2516590051C90924648 @default.
- W2516590051 hasIssue "15_suppl" @default.
- W2516590051 hasLocation W25165900511 @default.
- W2516590051 hasOpenAccess W2516590051 @default.
- W2516590051 hasPrimaryLocation W25165900511 @default.
- W2516590051 hasRelatedWork W1988917052 @default.
- W2516590051 hasRelatedWork W2010862449 @default.
- W2516590051 hasRelatedWork W2051017580 @default.
- W2516590051 hasRelatedWork W2158035792 @default.
- W2516590051 hasRelatedWork W2183352065 @default.
- W2516590051 hasRelatedWork W2418762493 @default.
- W2516590051 hasRelatedWork W247605849 @default.
- W2516590051 hasRelatedWork W2516590051 @default.
- W2516590051 hasRelatedWork W2780049887 @default.
- W2516590051 hasRelatedWork W2991935874 @default.
- W2516590051 hasVolume "28" @default.
- W2516590051 isParatext "false" @default.
- W2516590051 isRetracted "false" @default.
- W2516590051 magId "2516590051" @default.
- W2516590051 workType "article" @default.